Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity

• Yurpeak® is a prescription medicine and should be used under medical advice

• Will be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths

Visakhapatnam 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today
announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity
and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges. Cipla has
the rights to distribute and promote Yurpeak® — the second brand of Lilly’s tirzepatide in India, after Lilly
received DCGI approval.
Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: “The
launch of Yurpeak® marks a transformative moment in the fight against obesity and type 2 diabetes
mellitus, two of India’s chronic conditions with a heavy burden. Cipla is entering this space with the same
depth of expertise and scientific commitment that define our leadership in chronic diseases and in
respiratory care. Our focus remains on accelerating access to globally benchmarked, future-ready
therapies through collaborations like ours with Lilly, which bring together innovation, purpose, and scale
to ensure advanced care reaches patients wherever they are.”
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment
of Type 2 diabetes and Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI
≥ 27) with at least one weight-related comorbidity.
Yurpeak® will be available on prescription in the KwikPen® device format in six strengths: 2.5 mg, 5 mg,
7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.
Launch of Yurpeak® in India will help expand access to tirzepatide so that more patients can benefit from
this innovative therapy. Cipla’s strategic priority is to make it available across India, including regions
beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater
nationwide reach and accessibility. Lilly will manufacture and supply Yurpeak® to Cipla, and the price will
be the same as Mounjaro®.
Cipla will complement the launch of Yurpeak® with comprehensive patient education and support
programs, including guidance on dosing, self-administration, and safe, informed use of the therapy.
These initiatives are designed to help patients navigate their treatment confidently and responsibly, in
consultation with their healthcare professionals. This approach is backed by Cipla’s long-standing
commitment to evidence-based communication and responsible care, empowering individuals to make
timely health decisions and adopt sustainable wellness practices.